Citation

Quera-Salva MA, McCann C, Boudet J, Frisk M, Borderies P, Meyer P. Br. J. Clin. Pharmacol. 1994; 37(6): 539-543.

Affiliation

Unité de Sommeil, Hôpital Raymond Poincaré, Garches, France.

Copyright

(Copyright © 1994, John Wiley and Sons)

DOI

unavailable

PMID

7917771

PMCID

PMC1364812

Abstract

1. In a double-blind, crossover, placebo controlled trial, zolpidem 10 mg, a new imidazopyridine hypnotic drug, was administered in a single dose to 10 healthy non-obese heavy snorers. 2. Nocturnal polysomnography showed that zolpidem increased total sleep time, sleep efficiency and the percentage of stage 2. 3. Respiratory monitoring showed that zolpidem did not modify the percentage of total sleep time spent snoring. The percentages of total sleep time with a SaO2 < 4% of the baseline value and with a SaO2 < 90% and the mean SaO2 were also unchanged with zolpidem. The respiratory disturbance index was modestly increased by zolpidem although in all but one subject it remained < 5 with both treatments. 4. Zolpidem intake did not impair daytime vigilance and performance evaluated the day after.

Language: en